HUP0302201A2 - Oldható CTLA4 mutáns molekulák és alkalmazásuk - Google Patents

Oldható CTLA4 mutáns molekulák és alkalmazásuk

Info

Publication number
HUP0302201A2
HUP0302201A2 HU0302201A HUP0302201A HUP0302201A2 HU P0302201 A2 HUP0302201 A2 HU P0302201A2 HU 0302201 A HU0302201 A HU 0302201A HU P0302201 A HUP0302201 A HU P0302201A HU P0302201 A2 HUP0302201 A2 HU P0302201A2
Authority
HU
Hungary
Prior art keywords
ctla4
soluble
soluble ctla4
ctla4 mutant
fusion protein
Prior art date
Application number
HU0302201A
Other languages
English (en)
Inventor
Jurgen Bajorath
Peter S. Linsley
Joseph R. Naemura
Robert J. Peach
Original Assignee
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co. filed Critical Bristol-Myers Squibb Co.
Publication of HUP0302201A2 publication Critical patent/HUP0302201A2/hu
Publication of HUP0302201A3 publication Critical patent/HUP0302201A3/hu
Publication of HU228137B1 publication Critical patent/HU228137B1/hu
Priority to HUS1300012C priority Critical patent/HUS1300012I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány olyan oldható CTLA4 mutáns molekulákra vonatkozik, amelyekfelismerik és erősebb aviditással kötik a CD80-at és CD86-ot, mint avad típusú CTLA4. A találmány szerinti oldható CTLA4 mutáns molekulaegy fúziós protein, amely egy szignálpeptidet, a CTLA4 extracellulárisdoménjét és a humán immunglobulin egy konstans régióját tartalmazza. Amutagenezist helyre irányuló mutagenezissel, PCR alkalmazásávalvégzik. A mutagenizált fúziós proteint pedig géntechnológiaieljárásokkal állítják elő. A találmány szerinti oldható CTLA4Ig mutánsmolekula olyan immunrendszeri betegségek kezelésére alkalmazható, aholimmunszuppresszióra van szükség. Ilyenek pédául az autoimmunbetegségek, immunproliferatív betegségek, szövetátültetés utánikilökődés (graft versus host) stb. Ó
HU0302201A 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof HU228137B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HUS1300012C HUS1300012I1 (hu) 2000-05-26 2013-04-12 Oldható CTLA4 mutáns molekulák és alkalmazásuk

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (3)

Publication Number Publication Date
HUP0302201A2 true HUP0302201A2 (hu) 2003-10-28
HUP0302201A3 HUP0302201A3 (en) 2010-01-28
HU228137B1 HU228137B1 (en) 2012-12-28

Family

ID=26908652

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0302201A HU228137B1 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof
HUS1300012C HUS1300012I1 (hu) 2000-05-26 2013-04-12 Oldható CTLA4 mutáns molekulák és alkalmazásuk

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1300012C HUS1300012I1 (hu) 2000-05-26 2013-04-12 Oldható CTLA4 mutáns molekulák és alkalmazásuk

Country Status (41)

Country Link
EP (3) EP3029062A1 (hu)
JP (1) JP4328525B2 (hu)
KR (2) KR100895134B1 (hu)
CN (2) CN101255192A (hu)
AR (1) AR031699A1 (hu)
AT (1) ATE271066T1 (hu)
AU (2) AU2001263466C1 (hu)
BE (1) BE2011C041I2 (hu)
BR (1) BRPI0111191B8 (hu)
CA (1) CA2409748C (hu)
CY (2) CY2011019I1 (hu)
CZ (1) CZ304451B6 (hu)
DE (2) DE60104282T2 (hu)
DK (1) DK1248802T3 (hu)
EC (1) ECSP024365A (hu)
EE (2) EE05458B1 (hu)
EG (1) EG24459A (hu)
ES (2) ES2571852T3 (hu)
FR (1) FR11C0053I2 (hu)
GE (1) GEP20053658B (hu)
HK (2) HK1048126B (hu)
HU (2) HU228137B1 (hu)
IL (1) IL152315A (hu)
LT (1) LT5133B (hu)
LU (1) LU91902I2 (hu)
LV (1) LV12994B (hu)
MX (1) MXPA02011534A (hu)
MY (1) MY136113A (hu)
NO (2) NO330797B1 (hu)
PE (1) PE20011338A1 (hu)
PL (1) PL206267B1 (hu)
PT (1) PT1248802E (hu)
RU (1) RU2283847C2 (hu)
SI (1) SI1248802T1 (hu)
SK (1) SK288131B6 (hu)
TR (1) TR200402703T4 (hu)
TW (2) TWI314933B (hu)
UA (1) UA87432C2 (hu)
UY (1) UY26723A1 (hu)
WO (1) WO2001092337A2 (hu)
ZA (1) ZA200208944B (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
TWI322153B (en) * 2000-07-03 2010-03-21 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
DE60225914T2 (de) 2001-05-23 2009-07-23 Bristol-Myers Squibb Co. Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen
CA2482042A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
BR0316882A (pt) 2002-12-23 2005-10-25 Bristol Myers Squibb Co Melhora na qualidade de produtos em processos de cultura de células de mamìferos para a produção de proteìnas
US7541164B2 (en) 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
PT1969007E (pt) * 2005-12-20 2013-12-10 Bristol Myers Squibb Co Composições e métodos para a produção de uma composição
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
EP2121756A4 (en) 2006-12-20 2011-08-31 Mmrglobal Inc ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE
US7794718B2 (en) 2007-11-01 2010-09-14 Perseid Therapeutics, LLC Immunosuppressive polypeptides and nucleic acids
PT2344540T (pt) * 2008-10-02 2018-02-02 Aptevo Res & Development Llc Proteínas de ligação multi-alvo antagonistas de cd86
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
TW201134481A (en) * 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses
KR20130129438A (ko) 2011-02-23 2013-11-28 암젠 인크 Uvc 노출을 위한 세포 배양 배지 및 이와 관련된 방법
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
WO2013148049A1 (en) * 2012-03-29 2013-10-03 The General Hospital Corporation Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
AU2013260172B2 (en) * 2012-05-11 2017-11-23 Medimmune Limited CTLA-4 variants
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
AU2013284460A1 (en) * 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
SG11201605640UA (en) 2014-01-13 2016-08-30 Amgen Inc Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
SG11201610143VA (en) 2014-06-04 2017-01-27 Amgen Inc Methods for harvesting mammalian cell cultures
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
SI3283508T1 (sl) 2015-04-17 2021-09-30 Alpine Immune Sciences, Inc. Imunomodulirajoči proteini z nastavljivimi afinitetami
WO2017044807A2 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
EP3374493A1 (en) 2015-11-09 2018-09-19 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
CA3036997A1 (en) * 2016-09-19 2018-03-22 Oncoimmune, Inc. Cytotoxic t-lymphocyte-associated antigen-4(ctla-4)-fc fusion proteins and use thereof for treating adverse events associated with cancer immunotherapy
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
JP2020536552A (ja) 2017-10-10 2020-12-17 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ−４変異型免疫調節タンパク質およびそれらの使用
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
MX2022002337A (es) 2019-08-27 2022-06-08 Tonix Pharma Ltd Polipéptidos de tff2 modificados.
BR112021025769A2 (pt) 2019-12-06 2022-04-12 Regeneron Pharma Composições de proteína anti-vegf e métodos para a produção das mesmas
EP4168807A1 (en) 2020-06-18 2023-04-26 Regeneron Pharmaceuticals, Inc. Heavy peptide approach to accurately measure unprocessed c-terminal lysine
CA3189533A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
WO2023115027A2 (en) 2021-12-16 2023-06-22 Bristol-Myers Squibb Company Detergent for viral inactivation
US20230332201A1 (en) 2022-03-02 2023-10-19 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU661854B2 (en) * 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
WO2000019988A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
TWI322153B (en) * 2000-07-03 2010-03-21 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule

Also Published As

Publication number Publication date
PL206267B1 (pl) 2010-07-30
HUP0302201A3 (en) 2010-01-28
NO2011027I2 (hu) 2011-12-15
ATE271066T1 (de) 2004-07-15
SI1248802T1 (en) 2005-02-28
TWI314933B (en) 2009-09-21
UY26723A1 (es) 2001-12-28
HK1048126A1 (en) 2003-03-21
KR100895134B1 (ko) 2009-05-04
JP4328525B2 (ja) 2009-09-09
EP1536234A2 (en) 2005-06-01
UA87432C2 (uk) 2009-07-27
CA2409748C (en) 2008-09-16
EP1536234B1 (en) 2016-03-16
AR031699A1 (es) 2003-10-01
ZA200208944B (en) 2004-02-13
ECSP024365A (es) 2003-03-31
EE200200659A (et) 2004-06-15
EP1248802B9 (en) 2005-05-11
MY136113A (en) 2008-08-29
EE201100050A (et) 2011-10-17
NO20025656D0 (no) 2002-11-25
EP1248802B1 (en) 2004-07-14
CZ20023892A3 (cs) 2003-09-17
ES2225549T3 (es) 2005-03-16
WO2001092337A2 (en) 2001-12-06
DE122011100063I1 (de) 2012-06-14
AU2001263466B2 (en) 2006-04-27
EE05458B1 (et) 2011-08-15
AU6346601A (en) 2001-12-11
FR11C0053I1 (hu) 2012-01-13
BRPI0111191B8 (pt) 2021-05-25
NO330797B1 (no) 2011-07-18
HK1071931A1 (zh) 2005-08-05
ES2571852T3 (es) 2016-05-27
CZ304451B6 (cs) 2014-05-14
IL152315A0 (en) 2003-05-29
BRPI0111191B1 (pt) 2019-12-31
IL152315A (en) 2010-04-15
EE05557B1 (et) 2012-08-15
SK288131B6 (sk) 2013-10-02
WO2001092337A3 (en) 2002-05-10
BR0111191A (pt) 2004-07-06
TW200906857A (en) 2009-02-16
RU2283847C2 (ru) 2006-09-20
CN1441810A (zh) 2003-09-10
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
DE60104282D1 (de) 2004-08-19
CY1117625T1 (el) 2017-04-26
CA2409748A1 (en) 2001-12-06
LT5133B (lt) 2004-05-25
PT1248802E (pt) 2004-11-30
KR100889887B1 (ko) 2009-03-24
DE60104282T2 (de) 2005-10-13
EP3029062A1 (en) 2016-06-08
TR200402703T4 (tr) 2004-11-22
FR11C0053I2 (fr) 2013-01-11
CY2011019I1 (el) 2016-12-14
MXPA02011534A (es) 2004-08-12
HK1048126B (zh) 2005-03-04
EG24459A (en) 2009-07-16
HU228137B1 (en) 2012-12-28
PL366231A1 (en) 2005-01-24
KR20030009502A (ko) 2003-01-29
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
PE20011338A1 (es) 2002-01-13
SK15702002A3 (sk) 2004-01-08
LT2002114A (en) 2003-12-29
CN101255192A (zh) 2008-09-03
JP2004511213A (ja) 2004-04-15
LV12994B (en) 2003-08-20
HUS1300012I1 (hu) 2016-08-29
AU2001263466C1 (en) 2006-10-26
NO2011027I1 (no) 2012-01-09
BE2011C041I2 (hu) 2020-08-20
GEP20053658B (en) 2005-11-10
TWI319405B (en) 2010-01-11
EP1536234A3 (en) 2009-06-03
NO20025656L (no) 2002-11-25
CN1309735C (zh) 2007-04-11
DK1248802T3 (da) 2004-11-15

Similar Documents

Publication Publication Date Title
HUP0302201A2 (hu) Oldható CTLA4 mutáns molekulák és alkalmazásuk
JP2024019176A (ja) 系統特異的タンパク質の阻害のための組成物および方法
JP2022535130A (ja) 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体
HRP20211744T1 (hr) Poboljšana molekula polipeptida dvostruke specifičnosti
JP2020178690A (ja) 多部分シグナル伝達タンパク質およびその使用
HUP0303428A2 (hu) Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
AU3889399A (en) Vaccine delivery system
Hünig et al. CD28 superagonists: mode of action and therapeutic potential
EP0942973B1 (fr) Mutants de la proteine lag-3, leur expression et utilisation
CN107207622B (zh) Hla-b27同二聚体用于癌症治疗的用途
CN114729367A (zh) 用于cll1修饰的组合物和方法
KR20160010466A (ko) Ｉｃｏｓｌ에 대한 치료학적 표적 특이적 ｖｎａｒ 도메인의 단리
JP2023534460A (ja) コンジュゲーション部位を有するｔ細胞調節性ポリペプチド及びその使用方法
Al-Mossawi et al. The role of natural killer cells, gamma delta T-cells and other innate immune cells in spondyloarthritis
IL145795A (en) Mutant human cd80 and compositions for and methods of making and using the same
Richens et al. The detection of ADAM8 protein on cells of the human immune system and the demonstration of its expression on peripheral blood B cells, dendritic cells and monocyte subsets
JP2021511793A (ja) Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
Lake et al. Construction and binding analysis of recombinant single-chain TCR derived from tumor-infiltrating lymphocytes and a cytotoxic T lymphocyte clone directed against MAGE-1
Kierkels et al. Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells
EP4126962A1 (en) Cd3-fusion protein and uses thereof
Schroeder Jr et al. Antigen receptor genes, gene products, and coreceptors
Rijkers et al. Antibody diversity and B lymphocyte-mediated immunity
Matthey et al. pBM1. 1, a new pET-based vector for high efficiency expression of ETA'fusion toxins
Hwang et al. Analysis of T cell receptor alpha-chain variable region (Vα) usage and CDR3α of T cells infiltrated into lesions of psoriasis patients
WO2023205796A3 (en) Human ctla-4 peptide vaccines and uses thereof

Legal Events

Date Code Title Description
AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: BELATACEPT; REG. NO/DATE: EU/1/11/694/001-002 20110617

Spc suppl protection certif: S1300012

Filing date: 20130412

Expiry date: 20210523

FG4S Grant of supplementary protection certificate

Free format text: PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: EU/1/11/694/001-002 20110623

Spc suppl protection certif: S1300012

Filing date: 20130412

Expiry date: 20210523

Extension date: 20260523